| |
The challenges in cancer research are vast. Find a partner who can help you overcome them. With expertise ranging from small dose-finding studies to large multinational trials, we understand how to take an asset from concept to commercialization. Let’s navigate the path. Together.
Premier Research. Built for Biotech℠
|
|
Today's Big NewsMay 30, 2023 |
| By Nick Paul Taylor Pfizer is looming large in Novo Nordisk’s rearview mirror. Weeks after seeing its rival for the hemophilia market stumble, Pfizer has reported phase 3 data that suggest its candidate is competitive and position it to file for approval in the coming months. |
|
|
|
By James Waldron After swooping in to pluck Jounce out of the clutches of another potential buyer, Concentra could have been forgiven for thinking their next acquisition just weeks later would be another slam dunk. But their latest target, Atea, is proving less obliging. |
By Gabrielle Masson The departures of 2021's three highest paid R&D executives from Big Pharma threw a curveball at our annual list, prompting us to trim the feature down to five leaders. |
By Gabrielle Masson When it rains, it pours, an old adage that Rain Oncology hasn’t been able to shelter from. After a phase 3 fail, the precision oncology biotech is saying farewell to its chief medical officer, halting programs and laying off 65% of its workforce. |
By Annalee Armstrong C4 Therapeutics is handing over the rights to a lung cancer med in greater China for $10 million upfront and a shot to receive $357 million down the line. |
By Max Bayer GreenLight Biosciences will seek its dream off Wall Street in a go-private deal less than two years after taking the SPAC route there. |
By James Waldron Exicure’s significant layoffs and recent shelving of research activities haven’t yet attracted a transaction to save the remainder of the business. The biotech’s recently appointed joint CEO and CFO is now stepping up to find a solution. |
By Nick Paul Taylor Anew Medical has found a way to fund development of its neurodegenerative disease gene therapies. By merging with a blank check company, the biotech plans to land a Nasdaq listing and $54 million in cash, provided investors don’t pull their money before the deal closes. |
By Andrea Park XtalPi’s artificial intelligence- and robotics-powered technologies have helped its pharmaceutical partners pinpoint dozens of small-molecule compounds that could potentially be further developed into novel therapeutics—and Eli Lilly wants a piece of the AI drug development pie. |
By Kevin Dunleavy It’s been a winding road, but Lexicon has reached its destination, gaining an FDA approval for Inpefa (sotagliflozin). The once-daily pill becomes the first SGLT1/SGLT2 inhibitor to reach the market. It has been sanctioned to reduce the risk of heart failure. |
By Ben Adams While lung cancer survival rates have been going up in recent years, there’s an uneven benefit, with Black Americans much less likely to be diagnosed at an early stage. |
By Kevin Dunleavy Sun Pharma of India is on the verge of completing an acquisition that began with a buyout offer in 2007, gaining full control of Taro Pharmaceutical Industries. Sun, which already owns 78.5% of Taro, has offered to buy the remaining shares for $38 each. The deal would come to $307 million. |
Fierce podcastsDon't miss an episode |
| This week on "The Top Line," we discuss the 20 most influential people in biopharma, plus a topical gene therapy, a new opioid overdose medication, and the rest of the week's headlines. |
|
|---|
|
|
| WhitepaperThis paper outlines various market archetypes and key considerations leaders must address when prioritizing new potential markets for gene therapies. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| WhitepaperChatGPT shows promise in drug discovery for information extraction, scientific text authoring, hypothesis prediction, and chemical entity prediction. This whitepaper explores its potential to streamline research, delving into its technology, applications, and limitations. Sponsored by: Elucidata Corp., Cloud SAAS in Life Sciences R&D |
| WhitepaperLearn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| eBookDiscover a game-changing approach to clinical research with Hybrid and Decentralized Clinical Trials (DCTs). Learn about the benefits, challenges, and key elements for success. Sponsored by: EvidentIQ |
| Research What role do the Library and Legal teams play in the drug development pipeline at Lilly? An import one – find out how. Sponsored by: CCC |
| WhitepaperThis paper focuses on stakeholder engagement and how Medical Affairs teams’ responsibilities, goals, tools, and techniques are changing. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| ResearchStrategies for Optimal Site Selection and Feasibility Research in Novel Therapies and Geographies Sponsored by: H1 |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
| WhitepaperFor sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| WhitepaperHow can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| |
|
